EuroPCR 2018 | SPYRAL HTN-ON MED: Renal Denervation Comes Back to Life

After several trials with neutral outcomes, renal denervation had been demoted for some time. However, this new study presented at EuroPCR 2018 and simultaneously published in the LANCET brings back the technique with improved devices that seem to yield improved outcomes.

 SPYRAL HTN-ON MED: La denervación renal vuelve a la vidaThe study included patients with uncontrolled arterial hypertension under medical treatment.

 

Eligible patients had office systolic blood pressure (BP) between 150 and 180 mmHg, and office diastolic BP ≥90 mmHg, or 24 hr. ambulatory BP between 140 and 170 mmHg, in addition to having received at least 3 antihypertensive drugs with stable doses for a period of 6 weeks.


Read also: EuroPCR 2018 | NOTION: Good TAVR Durability Compared with Surgically-Implanted Valve in Low-Risk Patients.


All patients received renal angiography and were randomized, single-blind, sham-controlled to renal denervation vs. placebo.

 

It included 467 patients. This study reports the first 80 randomized patients, 38 receiving renal denervation vs. 42 receiving placebo.

 

24 hr. ambulatory arterial BP was significantly reduced from baseline to 6 months in the renal denervation group (mean reduction for systolic BP was 7 mmHg; p=0.0059, and 4.3 mmHg for diastolic BP; p=0.0174).


Read also: EuroPCR 2018 | SYNTAX III REVOLUTION: Excellent Correlation Between Angiography and Computerized Tomography in Patients with Left Main and Multivessel Disease.


Treatment compliance was por and close to 60%.

 

Título original: SPYRAL HTN-ON MED: six-month results from the randomized, blinded, sham- controlled trial on renal denervation in the presence of antihypertensive medications.

Presentador: David E. Kandzari.

 

SPYRAL-HTN-ON-MED

SPYRAL-HTN-ON-MED-articulo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....